Newcastle University: Company Research Report

Company Overview

Name: Newcastle University

Mission of the Company: Newcastle University is a world-leading institution, advancing knowledge, providing creative solutions, and addressing global problems.

Founded: No information is available.

Founders: No information is available.

Key People:

• Professor Ruth Plummer (Director of the Cancer Research UK Newcastle Centre, honorary consultant medical oncologist at the Freeman Hospital)

• Emeritus Professor Herbie Newell (Emeritus Professor of Cancer Therapeutics)

• Professor Hilary Calvert, Professor Nicola Curtin, Professor Barbara Durkacz, Professor Bernard Golding, Professor Roger Griffin, Honorary Professor Ruth Plummer (Researchers involved in the drug discovery work)

Headquarters: Newcastle upon Tyne, NE1 7RU, United Kingdom

Number of Employees: No information is available.

Revenue: No information is available.

Known For: Newcastle University is known for its pioneering work in cancer research, particularly in the development of the cancer drug rucaparib, a PARP inhibitor used for targeted cancer treatment.

Products

Products Offered:

• Rucaparib (Rubraca®)

• Description: Rucaparib is a cancer treatment drug developed as a PARP inhibitor to stop cancer cells from repairing themselves, specifically targeting tumors with BRCA gene mutations.

• Key Features:

• Approved by FDA in 2016 and NHS in 2019.

• Provides a treatment option for women with advanced ovarian cancer with BRCA mutations.

• Represents a revolutionary approach in preventing, diagnosing, and treating BRCA mutation-driven cancers.

Recent Developments

Recent Developments:

• Anniversary Celebration: Newcastle University scientists celebrated the 30th anniversary of the BRCA gene mutation discovery, which was pivotal in developing PARP inhibitors like rucaparib.

• Research Breakthrough: The researchers at Newcastle University, along with their Cancer Research UK partners, marked a landmark discovery that significantly impacted BRCA mutation-driven cancer treatment.

New Products Launched: No new products were mentioned.

New Features Added to Existing Products: No new features were mentioned.

Partnerships:

• Cancer Research UK played a critical role in backing the research and development of the drug with funding and provided collaboration opportunities for further advancements in this field.

Additional Information:

• The discovery of PARP inhibitors resulted in rucaparib becoming a global treatment for tens of thousands of patients and generating significant royalties reinvested into further cancer research by Cancer Research UK.